Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period. This unaudited filing covers the three and six months ended March 31, 2023, the company’s fiscal second quarter. Citius is a development-stage biopharmaceutical company focused on oncology, anti-infectives, prescription products, and stem cell therapies. It reported no operating revenue in either period.
Financial performance and liquidity
| Metric | Three months ended March 31, 2023 | Six months ended March 31, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.73 million | $8.17 million |
| General and administrative expense | $4.79 million | $7.40 million |
| Total operating expenses / operating loss | $10.69 million | $17.94 million |
| Net loss | $10.53 million | $14.12 million |
| Basic and diluted loss per share | $0.07 | $0.10 |
| Net cash used in operating activities | Not presented for quarter | $12.68 million |
For the six-month period, interest income was $0.52 million and a $3.59 million gain from selling New Jersey tax net operating losses reduced the reported net loss. The company recorded $0.29 million of income tax expense. Gross margin is not meaningful because there were no revenues.
Cash and cash equivalents were $29.07 million at March 31, 2023, down from $41.71 million at September 30, 2022. Working capital was approximately $28.7 million. Total liabilities were $12.43 million, including $5.85 million of deferred tax liability and $0.58 million of operating lease liabilities; the balance sheet reports no borrowings. Stockholders’ equity was $91.81 million.
Material changes versus comparable periods
- Quarterly net loss increased to $10.53 million from $7.56 million a year earlier, mainly as R&D expense rose $1.27 million and G&A rose $1.68 million.
- Six-month net loss narrowed to $14.12 million from $16.79 million. A $3.59 million tax-loss sale gain and higher interest income more than offset increased operating expenses and income tax expense.
- Six-month R&D expense fell $0.74 million overall: lower I/ONTAK costs following completion of its Phase 3 trial and BLA filing were partly offset by higher Mino-Lok and Halo-Lido trial costs.
- Six-month G&A expense increased $1.38 million, primarily from I/ONTAK pre-launch and market research activities. Stock-based compensation increased to $2.37 million from $1.93 million.
Outlook, commentary, and risks
- Management expected R&D expense to stabilize in fiscal 2023 while focusing on I/ONTAK commercialization and completing the Mino-Lok Phase 3 and Halo-Lido Phase 2b trials.
- Halo-Lido Phase 2b enrollment was reported complete on April 3, 2023; results were anticipated by the end of the second quarter of 2023. Mino-Lok trial activity included expansion to additional sites outside the United States. The I/ONTAK BLA had been filed with the FDA in September 2022.
- Management estimated that cash resources, including the subsequent offering, would fund operations through May 2024. Continued operations beyond then depend on product approvals and commercialization, revenue generation, or additional financing; the company gave no assurance that these outcomes or financing would be achieved.
- On May 8, 2023, after quarter-end, the company closed a registered direct offering of 12.5 million shares with warrants to purchase up to 12.5 million shares, generating $15.0 million in gross proceeds before expenses. The warrants have a $1.50 exercise price and a five-year term; the placement agent also received 875,000 warrants.
- Potential dilution is material: at March 31, 2023, 38.19 million warrants and 13.43 million stock-plan options were outstanding, with 11.81 million additional plan shares available for grants. The filing lists 63.43 million shares reserved for future issuance in total.
- License agreements include substantial contingent development, regulatory, and commercial milestones and royalties, including up to $40 million in I/ONTAK CTCL development milestones payable to Dr. Reddy’s, up to $70 million for additional indications, and up to $51 million under the NoveCite license. Payments are contingent on specified milestones.
- Key risks include clinical and regulatory outcomes, commercialization, the ability to raise capital, and dependence on partners and key personnel. The company reported no legal proceedings and no change in risk factors from its most recent Form 10-K.
Important facts for investors to verify
- Progress and timing of FDA review and potential approval of I/ONTAK, and the costs and commercial requirements associated with launch.
- Mino-Lok Phase 3 status and Halo-Lido Phase 2b results, including whether the expected timing or development plans changed.
- Actual cash burn, financing needs, and whether available resources remain sufficient to support operations through the stated May 2024 estimate.
- Offering costs, warrant terms and potential exercise proceeds, and the resulting share count and dilution.
- Future contingent license payments, royalty obligations, and whether any milestone triggers or commercialization commitments have been met.